Lymphoma B3281006

April 27, 2017

Sponsor: Pfizer

Number: B3281006 

This study will compare the safety and effectiveness of PF-05280586 versus Rituximab-EU in patients with CD20-positive, low tumor burden follicular lymphoma. The primary hypothesis to be tested in this study is that the effectiveness of PF-05280586, as measured by the Overall Response Rate, is similar to that of Rituximab-EU.

Who’s eligible:

  • Patient must have a confirmed diagnosis of low tumor burden, CD20-positive (a specific white blood cell) follicular lymphoma, and Ann Arbor Stage II, III, or IV. Arbor stage IV depends on both the place where the malignant tissue is located and on systemic symptoms due to the lymphoma).
  • This study is for patients age 18 and older.

Available at: The Hospital of Central Connecticut- The Cancer Center of Central Connecticut.

Cancer Clinical Research Office